Recruiting
Phase 2

Sacituzumab Govitecan & Pembrolizumab

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT04468061

Conditions

Breast Cancer

Triple Negative Breast Cancer

PD-L1 Negative

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-04-29.